This study is for patients with advanced solid tumors. The purpose of this study is to test
the safety and effectiveness of a new combination of drugs, CS-7017 and Bexarotene in
patients with advanced cancer. CS-7017 and Bexarotene both have many effects on cancer cells,
including stopping cancer cells from growing and dividing, and causing the cancer cells to
die. CS-7017 and Bexarotene work on cancer cells in a similar manner and both drugs together
may have an even greater effect against cancer cells, hopefully, increasing the killing of
cancer cells.
CS-7017 is an investigational or experimental anti-cancer agent that has not yet been
approved by the Food and Drug Administration (FDA) for use in any type of cancer. Bexarotene
is an anti-cancer agent that has been approved by the FDA for patients with a specific type
of cancer, cutaneous T-cell lymphoma.
This study will help find out what effects the combination of drugs, CS-7017 and Bexarotene,
has on cancer. This research is being done because it is not known if CS-7017 is safe to be
given with Bexarotene.